Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Oct 1 - Oct 6
Retatrutide is being studied in that same general category of peptide weight loss therapy , but with an important twist: it is designed as a triple-agonist. What that means is that retatrutide targets three receptors involved in weight regulation and metabolism: GLP-1 , which supports satiety and improves glucose control GIP , another incretin hormone involved in metabolic signaling Glucagon receptors , which are linked to energy balance and how the body uses fuel This three-pronged approach is a big reason its creating buzz
In a large 56-week clinical trial that evaluated liraglutide in individuals who were overweight or had obesity, as well as had diabetes or prediabetes, participants reported statistically significant weight loss compared with those who took the placebo at the end of the study
Notably, the extent of weight loss achieved with GLP-1 RA therapy may be directly linked to the degree of reduction in preference for high-calorie foods as semaglutide was associated with reduced cravings for both savory and sugary foods, with decreases in craving scores correlating with greater weight loss (Blundell et al., 2017
GLP-1 works through several complementary mechanisms
